XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue- Incyte Corporation (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 24 Months Ended 87 Months Ended
Aug. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jan. 31, 2022
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2020
Dec. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Jul. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
performanceObligation
Collaboration And Other Agreements [Line Items]                        
Revenues       $ 13,192 $ 9,104              
Deferred revenue, current       15,620         $ 15,620 $ 16,319    
Deferred revenue, net of current portion       55,938         55,938 55,503    
Incyte Corporation | Incyte MGA012 Agreement                        
Collaboration And Other Agreements [Line Items]                        
Non-refundable upfront payment             $ 150,000          
Potential commercial milestone payments under agreement                       $ 330,000
Potential development and regulatory milestone payments under agreement                       210,000
Development and regulatory milestones recognized $ 100,000               215,000      
Collaborative agreement transaction price                       $ 154,000
Variable consideration recognized               $ 4,000        
Number of performance obligations | performanceObligation                       2
Gilead | Gilead First Research Program                        
Collaboration And Other Agreements [Line Items]                        
Revenues   $ 3,300   5,400 700              
Deferred revenue       5,600         5,600 11,000    
Deferred revenue, current       5,600         5,600 11,000    
Minimum | Incyte Corporation | Incyte MGA012 Agreement                        
Collaboration And Other Agreements [Line Items]                        
Potential proceeds from royalties (percent)           15.00%            
Maximum | Incyte Corporation | Incyte MGA012 Agreement                        
Collaboration And Other Agreements [Line Items]                        
Potential proceeds from royalties (percent)           24.00%            
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                        
Collaboration And Other Agreements [Line Items]                        
Revenues       400 200   $ 150,000          
Revenues From License Agreements | Incyte Corporation | Incyte Commercial Supply Agreement                        
Collaboration And Other Agreements [Line Items]                        
Revenues       400 400              
RevenuesFromCMOAgreementsMember | Incyte Corporation                        
Collaboration And Other Agreements [Line Items]                        
Non-refundable upfront payment     $ 10,000                  
Annual Fixed Payments     $ 14,400                  
Revenues       5,000 $ 2,100              
Deferred revenue       1,800         1,800 3,400    
Deferred revenue, current       1,800         1,800 $ 3,400    
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                        
Collaboration And Other Agreements [Line Items]                        
Annual Fixed Payments       41,700         41,700      
Additional Payments       $ 13,500         $ 13,500   $ 5,100  
Manufacturing Services | Incyte Corporation                        
Collaboration And Other Agreements [Line Items]                        
Extension term                     1 year  
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01                        
Collaboration And Other Agreements [Line Items]                        
Revenue, remaining performance obligation, expected timing of satisfaction     3 years